Live from the NIH registry
Studies recruiting near Austin right now
Top 25 of 748 recruiting studies, sorted by proximity — each links to its official registry page
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer, c-MET
Phase 3
Interventional 768 participants sought
Dell Seton Medical Center /ID# 247016 — Austin, Texas (2.4 mi)
· Sponsor: AbbVie
Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform
Any Solid Oral Medication
N/A
Interventional 200 participants sought
Texas Oncology — Austin, Texas (2.4 mi)
· Sponsor: Dosentrx Ltd.
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
EARLY/Phase 1
Interventional 10 participants sought
Austin Neuromuscular Center — Austin, Texas (2.4 mi)
· Sponsor: Austin Neuromuscular Center
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Limited Stage Small Cell Lung Cancer
Phase 2
Interventional 250 participants sought
Texas Oncology- Austin — Austin, Texas (2.4 mi)
· Sponsor: SCRI Development Innovations, LLC
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma
Phase 2
Interventional 40 participants sought
Ohio State University-Telemedicine — Austin, Texas (2.4 mi)
· Sponsor: Sameek Roychowdhury
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Triple Negative Breast Cancer, HER2-negative Breast Cancer
Phase 1
Interventional 96 participants sought
Dren Investigational Site — Austin, Texas (2.4 mi)
· Sponsor: Dren Bio
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis, Ulcerative
Phase 3
Interventional 882 participants sought
The University of Texas at Austin — Austin, Texas (2.4 mi)
· Sponsor: Janssen Research & Development, LLC
GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
N/A
Interventional 400 participants sought
Texas Diabetes & Endocrinology — Austin, Texas (2.4 mi)
· Sponsor: Medtronic MiniMed, Inc.
The Pediatric Anesthesia Quality Improvement Project
Surgery, Anesthesia
N/A
Observational 5,000,000 participants sought
Dell Children's Medical Center of Central Texas — Austin, Texas (2.4 mi)
· Sponsor: The Society for Pediatric Anesthesia
PAS-004 in Patients With Advanced Solid Tumors
RAS Mutation, NF1 Mutation
Phase 1
Interventional 48 participants sought
NEXT Oncology — Austin, Texas (2.4 mi)
· Sponsor: Pasithea Therapeutics Corp.
Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
Neuroblastoma
Phase 2
Interventional 98 participants sought
Dell Children's Blood and Cancer Center — Austin, Texas (2.4 mi)
· Sponsor: Giselle Sholler
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
Ventricular Tachycardia (VT)
N/A
Interventional 60 participants sought
Texas Cardiac Arrhythmia Research Foundation — Austin, Texas (2.4 mi)
· Sponsor: Medtronic Cardiac Ablation Solutions
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer
Phase 3
Interventional 590 participants sought
Texas Oncology - South Austin — Austin, Texas (2.4 mi)
· Sponsor: Revolution Medicines, Inc.
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Lymphoma, Large B-Cell, Diffuse
Phase 2
Interventional 594 participants sought
Texas Oncology - Central/South Texas ( Site 8006) — Austin, Texas (2.4 mi)
· Sponsor: Merck Sharp & Dohme LLC
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Cancer, Bladder Cancer
Phase 2, Phase 3
Interventional 630 participants sought
Research Site — Austin, Texas (2.4 mi)
· Sponsor: Daiichi Sankyo
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 3
Interventional 450 participants sought
USO-Texas Oncology-Central/South Texas — Austin, Texas (2.4 mi)
· Sponsor: Eli Lilly and Company
Remotely-supervised Neuromodulation in PPA
Primary Progressive Aphasia(PPA), Progressive Aphasia
N/A
Interventional 80 participants sought
University of Texas — Austin, Texas (2.4 mi)
· Sponsor: Maya Henry
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
Narcolepsy
Phase 2
Interventional 64 participants sought
Future Search Trials of Neurology — Austin, Texas (2.4 mi)
· Sponsor: Eisai Inc.
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Neovascular Age-related Macular Degeneration
Phase 4
Interventional 188 participants sought
Austin Retina Associates — Austin, Texas (2.4 mi)
· Sponsor: Genentech, Inc.
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Neuroblastoma
Phase 2
Interventional 93 participants sought
Dell Children's Blood and Cancer Center — Austin, Texas (2.4 mi)
· Sponsor: Giselle Sholler
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)
Heart Failure
Phase 3
Interventional 1,500 participants sought
CON-10015 Austin, TX Investigational Site — Austin, Texas (2.4 mi)
· Sponsor: Colorado Prevention Center
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Oncology, MEK Mutation
Phase 1
Interventional 230 participants sought
NEXT Oncology - Austin — Austin, Texas (2.4 mi)
· Sponsor: Nested Therapeutics, Inc
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Chronic Migraine
Phase 3
Interventional 420 participants sought
UT Health Austin at Dell Childrens Neurology Clinic /ID# 270577 — Austin, Texas (2.4 mi)
· Sponsor: AbbVie
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Epithelial Ovarian Cancer, Fallopian Tube Cancer
Phase 2
Interventional 140 participants sought
Texas Oncology - Austin Central /ID# 275046 — Austin, Texas (2.4 mi)
· Sponsor: AbbVie
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
Phase 3
Interventional 600 participants sought
Research Site — Austin, Texas (2.4 mi)
· Sponsor: AstraZeneca